Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Apr 8;31(6):697–710. doi: 10.1038/s41418-024-01288-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a The experimental design. b Survival curves of AML recipients with WT or Prtn3^−/− AML cells (n = 10 per group). c histogram analysis of the percentage of GFP+ leukemia cells in the peripheral blood (PB) of recipients 30 days after transplantation (n = 6). d immunofluorescence staining assay shows GFP+ leukemia cells in the spleen of recipients 30 days after transplantation (n = 6). e The bone marrow color (left) and histogram (right) of recipient on 30 days after transplantation (n = 6). f Flow cytometry (left) and histogram (right) analysis show the percentages of neutrophils from AML cells (GFP+) in the BM of recipients (n = 6). g Histogram analysis shows the percentages of GFP+ neutrophils with PE-E.coli uptake from BM of AML^Prtn3KO recipients at different time points (n = 3). h Histogram analysis shows the percentages of GFP+ neutrophils capable of chemotaxis migration in the abdominal cavity of AML^Prtn3KO recipients with E. coli injection for 6 h (n = 3). i messenger RNA of Prtn3 expression in healthy peoples and patients (n = 6). j, k messenger RNA and protein expression of PRTN3 and β-Actin were analyzed in HL60 cells with Si-control or Si-Prtn3 treatment for 24 h (n = 3). l Flow cytometry (left) and histogram (right) analysis of the percentage of CD11b+ leukemia cells in the HL60 cells with Si-control or Si-Prtn3 treatment for 7 days (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001. Data are the mean ± s.d.; n: biologically independent experiments. Statistical analysis was performed using an unpaired two-tailed Student’s t test.